188 related articles for article (PubMed ID: 16102623)
21. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes.
Eikelboom JW; Weitz JI; Budaj A; Zhao F; Copland I; Maciejewski P; Johnston M; Yusuf S
Eur Heart J; 2002 Nov; 23(22):1771-9. PubMed ID: 12419297
[TBL] [Abstract][Full Text] [Related]
22. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Undas A; Stepień E; Branicka A; Wołkow P; Zmudka K; Tracz W
Kardiol Pol; 2009 Jun; 67(6):591-8. PubMed ID: 19618315
[TBL] [Abstract][Full Text] [Related]
23. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
[TBL] [Abstract][Full Text] [Related]
24. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
25. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial.
Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS
Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478
[TBL] [Abstract][Full Text] [Related]
26. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.
Strobl FF; Brechtel K; Schmehl J; Zeller T; Reiser MF; Claussen CD; Tepe G
J Endovasc Ther; 2013 Oct; 20(5):699-706. PubMed ID: 24093324
[TBL] [Abstract][Full Text] [Related]
27. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
28. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
29. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
30. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
Dallob A; Luo WL; Luk JM; Ratcliffe L; Johnson-Levonas AO; Schwartz JI; Dishy V; Kraft WK; De Hoon JN; Van Hecken A; De Lepeleire I; Radziszewski W; Wagner JA; Lai E
Platelets; 2011; 22(7):495-503. PubMed ID: 21526889
[TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
32. [Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Averkov OV; Slavina NN; Gratsianskiĭ NA
Kardiologiia; 2003; 43(10):50-9. PubMed ID: 14593356
[TBL] [Abstract][Full Text] [Related]
33. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
[TBL] [Abstract][Full Text] [Related]
34. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease.
van der Bom JG; Bots ML; Haverkate F; Meijer P; Hofman A; Kluft C; Grobbee DE
Thromb Haemost; 2001 Feb; 85(2):234-9. PubMed ID: 11246539
[TBL] [Abstract][Full Text] [Related]
35. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Chen YG; Xu F; Zhang Y; Ji QS; Sun Y; Lü RJ; Li RJ
Chin Med J (Engl); 2006 Jan; 119(1):32-6. PubMed ID: 16454979
[TBL] [Abstract][Full Text] [Related]
36. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.
Tang YD; Rinder HM; Katz SD
Am Heart J; 2007 Sep; 154(3):494.e1-7. PubMed ID: 17719296
[TBL] [Abstract][Full Text] [Related]
37. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
Bombeli T; Raddatz-Mueller P; Fehr J
Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
[TBL] [Abstract][Full Text] [Related]
38. Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease.
Walter T; Szabo S; Kazmaier S; Swoboda S; Suselbeck T; Brueckmann M; Borggrefe M; Beyer ME; Hoffmeister HM
J Cardiovasc Pharmacol; 2008 Jun; 51(6):616-20. PubMed ID: 18574391
[TBL] [Abstract][Full Text] [Related]
39. Intermittent pneumatic compression in stable claudicants: effect on hemostasis and endothelial function.
Sutkowska E; Wozniewski M; Gamian A; Gosk-Bierska I; Alexewicz P; Sutkowski K; Wysokinski WE
Int Angiol; 2009 Oct; 28(5):373-9. PubMed ID: 19935591
[TBL] [Abstract][Full Text] [Related]
40. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Gurbel PA; Bliden KP; Butler K; Tantry US; Gesheff T; Wei C; Teng R; Antonino MJ; Patil SB; Karunakaran A; Kereiakes DJ; Parris C; Purdy D; Wilson V; Ledley GS; Storey RF
Circulation; 2009 Dec; 120(25):2577-85. PubMed ID: 19923168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
